サマリー

経口薬は、振戦、こわばり、運動障害などの運動症状を特徴とする神経変性疾患であるパーキンソン病の治療の要である。これらの薬剤は主に、脳内の根本的なドパミン欠乏に対処することで、症状を管理し、生活の質を改善することを目的としています。最も一般的に処方される薬剤はレボドパで、副作用を最小限に抑えながらレボドパをドパミンに変換するカルビドパと併用されることが多い。その他の内服薬としては、ドパミンの作用を模倣するドパミンアゴニスト、脳内ドパミンの分解を防ぐMAO-B阻害薬、レボドパの効果を延長させるCOMT阻害薬、振戦を抑制する抗コリン薬などがある。抗ウイルス薬のアマンタジンも、症状やジスキネジアの管理に使用される。
世界のパーキンソン病経口薬市場は、2024年の100万米ドルから2030年には100万米ドルに成長し、予測期間中の年間平均成長率（CAGR）は％と予測されています。

米国とカナダのパーキンソン病用経口薬市場は、2024年の100万米ドルから2030年には100万米ドルに達すると予測され、2024年から2030年の予測期間中、年平均成長率（CAGR）は%である。
パーキンソン病用経口薬の中国市場は、2024年の100万ドルから2030年には100万ドルに達すると推定され、2024年から2030年の予測期間中の年平均成長率は%である。
パーキンソン病用経口薬のヨーロッパ市場は、2024年の100万ドルから2030年には100万ドルに達すると推定され、2024年から2030年の予測期間中の年平均成長率は%である。
パーキンソン病用経口薬の世界の主要メーカーは、AbbVie、Merck、Boehringer Ingelheim、GlaxoSmithKline、Novartis Pharma、Supernus Pharmaceuticals、Bausch Health、Newron Pharmaceuticals、Teva Pharmaceutica、Glenmark Pharmaceuticalsなどです。2023年、世界の上位5社の売上高シェアは約 %であった。

レポートの内容
本レポートでは、パーキンソン病用経口薬の世界市場概要、売上高、収益、価格を紹介しています。2019年～2023年の過去の市場収益/売上データ、2024年の予測、2030年までのCAGR予測による世界市場動向の分析。
本レポートでは、パーキンソン病用経口薬の主要生産者を調査し、主要地域・国の売上高も掲載しています。パーキンソン病用経口薬の今後の市場ポテンシャルと、この市場を様々なセグメントとサブセグメントに予測するための主要地域/国の注目点のハイライト。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他の国々の国別データと市場価値分析。

本レポートでは、2019年から2024年までのデータで、主要メーカーのパーキンソン病用経口薬の売上高、収益、市場シェア、業界ランキングに焦点を当てています。世界のパーキンソン病用経口薬市場における主要な利害関係者を特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別の収益に基づいて分析します。本レポートは、利害関係者が競争状況を理解し、より多くの洞察を得て、より良い方法で事業と市場戦略を位置づけるのに役立ちます。
本レポートでは、2019年から2030年までのタイプ別、用途別のセグメントデータ、売上高、収益、価格を分析しています。パーキンソン病用経口薬の売上高、予測成長動向、生産技術、用途、エンドユーザー産業の評価と市場規模の予測。
AbbVie、Merck、Boehringer Ingelheim、GlaxoSmithKline、Novartis Pharma、Supernus Pharmaceuticals、Bausch Health、Newron Pharmaceuticals、Teva Pharmaceutica、Glenmark Pharmaceuticalsなど、世界の主要企業の詳細な企業プロフィール

市場区分
企業別
アッヴィ
メルク
ベーリンガーインゲルハイム
グラクソ・スミスクライン
ノバルティスファーマ
スーパナス・ファーマシューティカルズ
ボシュ・ヘルス
ニューロン・ファーマシューティカルズ
テバ・ファーマスーティカ
グレンマーク製薬
オリオンファーマ
ニューロクライン・バイオサイエンス
協和キリン
UCB
デシチン
アムニール製薬
オルガノンファーマ
エフ・ホフマン・ラ・ロシュ
ルンドベック
スターダ
タイプ別セグメント
L-ドパ製剤
ドパミン作動薬
Mao-B阻害剤
COMT阻害剤
用途別セグメント
40歳未満
40～65歳
65歳以上
地域別セグメント
米国およびカナダ
米国
カナダ
中国
アジア（中国を除く）
日本
韓国
中国 台湾
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東、アフリカ、中南米
ブラジル
メキシコ
トルコ
イスラエル
GCC諸国

各章の概要
第1章：報告書のスコープ、各市場セグメント（タイプ別、用途別など）の市場規模、今後の発展可能性などのエグゼクティブサマリーを紹介。市場の現状と、短期・中期・長期的な展開の可能性について、ハイレベルな見解を提供しています。
第2章 世界、地域レベル、国レベルでのパーキンソン病経口薬の販売（消費）、収益。各地域と主要国の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場スペース、生産能力などを紹介しています。
第3章：パーキンソン病用経口薬メーカーの競争環境、価格、売上高、市場シェア、業界ランキング、最新の開発計画、合併・買収情報などを詳細に分析。
第4章：各種市場セグメントをタイプ別に分析し、各市場セグメントの売上高、収益、平均価格、発展可能性などを網羅し、読者が各市場セグメントのブルーオーシャン市場を見つけやすくします。
第5章：読者が異なる下流市場のブルーオーシャン市場を見つけるのを助けるために、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーする、アプリケーション別の様々な市場セグメントの分析を提供します。
第6章 北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。
第7章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高、収益。
第8章：中国：タイプ別、用途別、セグメント別の売上高、収益。
第9章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。
第10章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。
第11章：主要メーカーのプロファイルを提供し、製品の説明と仕様、パーキンソン病用経口薬の売上高、収益、価格、粗利益率、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介する。
第12章：産業チェーン、販売チャネル、主要原材料、流通業者、顧客の分析。
第13章：市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を紹介する。
第14章：レポートの要点と結論。

ページTOPに戻る

目次

1 Study Coverage
1.1 Oral Medications for Parkinson's Disease Product Introduction
1.2 Market by Type
1.2.1 Global Oral Medications for Parkinson's Disease Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 L-Dopa Formulations
1.2.3 Dopamine Agonists
1.2.4 Mao-B Inhibitors
1.2.5 COMT Inhibitors
1.3 Market by Application
1.3.1 Global Oral Medications for Parkinson's Disease Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Under 40 Years Old
1.3.3 40-65 Years Old
1.3.4 Above 65 Years Old
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oral Medications for Parkinson's Disease Revenue Estimates and Forecasts 2019-2030
2.2 Global Oral Medications for Parkinson's Disease Revenue by Region
2.2.1 Global Oral Medications for Parkinson's Disease Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Oral Medications for Parkinson's Disease Revenue by Region (2019-2024)
2.2.3 Global Oral Medications for Parkinson's Disease Revenue by Region (2025-2030)
2.2.4 Global Oral Medications for Parkinson's Disease Revenue Market Share by Region (2019-2030)
2.3 Global Oral Medications for Parkinson's Disease Sales Estimates and Forecasts 2019-2030
2.4 Global Oral Medications for Parkinson's Disease Sales by Region
2.4.1 Global Oral Medications for Parkinson's Disease Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Oral Medications for Parkinson's Disease Sales by Region (2019-2024)
2.4.3 Global Oral Medications for Parkinson's Disease Sales by Region (2025-2030)
2.4.4 Global Oral Medications for Parkinson's Disease Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Oral Medications for Parkinson's Disease Sales by Manufacturers
3.1.1 Global Oral Medications for Parkinson's Disease Sales by Manufacturers (2019-2024)
3.1.2 Global Oral Medications for Parkinson's Disease Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oral Medications for Parkinson's Disease in 2023
3.2 Global Oral Medications for Parkinson's Disease Revenue by Manufacturers
3.2.1 Global Oral Medications for Parkinson's Disease Revenue by Manufacturers (2019-2024)
3.2.2 Global Oral Medications for Parkinson's Disease Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Oral Medications for Parkinson's Disease Revenue in 2023
3.3 Global Key Players of Oral Medications for Parkinson's Disease, Industry Ranking, 2021 VS 2022
3.4 Global Oral Medications for Parkinson's Disease Sales Price by Manufacturers (2019-2024)
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Oral Medications for Parkinson's Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Oral Medications for Parkinson's Disease, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Oral Medications for Parkinson's Disease, Product Offered and Application
3.8 Global Key Manufacturers of Oral Medications for Parkinson's Disease, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Oral Medications for Parkinson's Disease Sales by Type
4.1.1 Global Oral Medications for Parkinson's Disease Historical Sales by Type (2019-2024)
4.1.2 Global Oral Medications for Parkinson's Disease Forecasted Sales by Type (2025-2030)
4.1.3 Global Oral Medications for Parkinson's Disease Sales Market Share by Type (2019-2030)
4.2 Global Oral Medications for Parkinson's Disease Revenue by Type
4.2.1 Global Oral Medications for Parkinson's Disease Historical Revenue by Type (2019-2024)
4.2.2 Global Oral Medications for Parkinson's Disease Forecasted Revenue by Type (2025-2030)
4.2.3 Global Oral Medications for Parkinson's Disease Revenue Market Share by Type (2019-2030)
4.3 Global Oral Medications for Parkinson's Disease Price by Type
4.3.1 Global Oral Medications for Parkinson's Disease Price by Type (2019-2024)
4.3.2 Global Oral Medications for Parkinson's Disease Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Oral Medications for Parkinson's Disease Sales by Application
5.1.1 Global Oral Medications for Parkinson's Disease Historical Sales by Application (2019-2024)
5.1.2 Global Oral Medications for Parkinson's Disease Forecasted Sales by Application (2025-2030)
5.1.3 Global Oral Medications for Parkinson's Disease Sales Market Share by Application (2019-2030)
5.2 Global Oral Medications for Parkinson's Disease Revenue by Application
5.2.1 Global Oral Medications for Parkinson's Disease Historical Revenue by Application (2019-2024)
5.2.2 Global Oral Medications for Parkinson's Disease Forecasted Revenue by Application (2025-2030)
5.2.3 Global Oral Medications for Parkinson's Disease Revenue Market Share by Application (2019-2030)
5.3 Global Oral Medications for Parkinson's Disease Price by Application
5.3.1 Global Oral Medications for Parkinson's Disease Price by Application (2019-2024)
5.3.2 Global Oral Medications for Parkinson's Disease Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Oral Medications for Parkinson's Disease Market Size by Type
6.1.1 US & Canada Oral Medications for Parkinson's Disease Sales by Type (2019-2030)
6.1.2 US & Canada Oral Medications for Parkinson's Disease Revenue by Type (2019-2030)
6.2 US & Canada Oral Medications for Parkinson's Disease Market Size by Application
6.2.1 US & Canada Oral Medications for Parkinson's Disease Sales by Application (2019-2030)
6.2.2 US & Canada Oral Medications for Parkinson's Disease Revenue by Application (2019-2030)
6.3 US & Canada Oral Medications for Parkinson's Disease Market Size by Country
6.3.1 US & Canada Oral Medications for Parkinson's Disease Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Oral Medications for Parkinson's Disease Revenue by Country (2019-2030)
6.3.3 US & Canada Oral Medications for Parkinson's Disease Sales by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Oral Medications for Parkinson's Disease Market Size by Type
7.1.1 Europe Oral Medications for Parkinson's Disease Sales by Type (2019-2030)
7.1.2 Europe Oral Medications for Parkinson's Disease Revenue by Type (2019-2030)
7.2 Europe Oral Medications for Parkinson's Disease Market Size by Application
7.2.1 Europe Oral Medications for Parkinson's Disease Sales by Application (2019-2030)
7.2.2 Europe Oral Medications for Parkinson's Disease Revenue by Application (2019-2030)
7.3 Europe Oral Medications for Parkinson's Disease Market Size by Country
7.3.1 Europe Oral Medications for Parkinson's Disease Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Oral Medications for Parkinson's Disease Revenue by Country (2019-2030)
7.3.3 Europe Oral Medications for Parkinson's Disease Sales by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Oral Medications for Parkinson's Disease Market Size by Type
8.1.1 China Oral Medications for Parkinson's Disease Sales by Type (2019-2030)
8.1.2 China Oral Medications for Parkinson's Disease Revenue by Type (2019-2030)
8.2 China Oral Medications for Parkinson's Disease Market Size by Application
8.2.1 China Oral Medications for Parkinson's Disease Sales by Application (2019-2030)
8.2.2 China Oral Medications for Parkinson's Disease Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Oral Medications for Parkinson's Disease Market Size by Type
9.1.1 Asia Oral Medications for Parkinson's Disease Sales by Type (2019-2030)
9.1.2 Asia Oral Medications for Parkinson's Disease Revenue by Type (2019-2030)
9.2 Asia Oral Medications for Parkinson's Disease Market Size by Application
9.2.1 Asia Oral Medications for Parkinson's Disease Sales by Application (2019-2030)
9.2.2 Asia Oral Medications for Parkinson's Disease Revenue by Application (2019-2030)
9.3 Asia Oral Medications for Parkinson's Disease Market Size by Region
9.3.1 Asia Oral Medications for Parkinson's Disease Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Oral Medications for Parkinson's Disease Revenue by Region (2019-2030)
9.3.3 Asia Oral Medications for Parkinson's Disease Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
9.3.9 Australia
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Market Size by Type
10.1.1 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Market Size by Application
10.2.1 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Market Size by Country
10.3.1 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Oral Medications for Parkinson's Disease Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Corporate Profile
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Overview
11.1.3 AbbVie Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 AbbVie Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AbbVie Recent Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Overview
11.2.3 Merck Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Merck Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Information
11.3.2 Boehringer Ingelheim Overview
11.3.3 Boehringer Ingelheim Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Boehringer Ingelheim Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Boehringer Ingelheim Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Information
11.4.2 GlaxoSmithKline Overview
11.4.3 GlaxoSmithKline Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 GlaxoSmithKline Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 GlaxoSmithKline Recent Developments
11.5 Novartis Pharma
11.5.1 Novartis Pharma Company Information
11.5.2 Novartis Pharma Overview
11.5.3 Novartis Pharma Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Novartis Pharma Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Novartis Pharma Recent Developments
11.6 Supernus Pharmaceuticals
11.6.1 Supernus Pharmaceuticals Company Information
11.6.2 Supernus Pharmaceuticals Overview
11.6.3 Supernus Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Supernus Pharmaceuticals Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Supernus Pharmaceuticals Recent Developments
11.7 Bausch Health
11.7.1 Bausch Health Company Information
11.7.2 Bausch Health Overview
11.7.3 Bausch Health Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Bausch Health Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Bausch Health Recent Developments
11.8 Newron Pharmaceuticals
11.8.1 Newron Pharmaceuticals Company Information
11.8.2 Newron Pharmaceuticals Overview
11.8.3 Newron Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Newron Pharmaceuticals Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Newron Pharmaceuticals Recent Developments
11.9 Teva Pharmaceutica
11.9.1 Teva Pharmaceutica Company Information
11.9.2 Teva Pharmaceutica Overview
11.9.3 Teva Pharmaceutica Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Teva Pharmaceutica Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Teva Pharmaceutica Recent Developments
11.10 Glenmark Pharmaceuticals
11.10.1 Glenmark Pharmaceuticals Company Information
11.10.2 Glenmark Pharmaceuticals Overview
11.10.3 Glenmark Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Glenmark Pharmaceuticals Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Glenmark Pharmaceuticals Recent Developments
11.11 Orion Pharma
11.11.1 Orion Pharma Company Information
11.11.2 Orion Pharma Overview
11.11.3 Orion Pharma Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.11.4 Orion Pharma Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Orion Pharma Recent Developments
11.12 Neurocrine Biosciences
11.12.1 Neurocrine Biosciences Company Information
11.12.2 Neurocrine Biosciences Overview
11.12.3 Neurocrine Biosciences Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.12.4 Neurocrine Biosciences Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Neurocrine Biosciences Recent Developments
11.13 Kyowa Kirin
11.13.1 Kyowa Kirin Company Information
11.13.2 Kyowa Kirin Overview
11.13.3 Kyowa Kirin Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.13.4 Kyowa Kirin Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Kyowa Kirin Recent Developments
11.14 UCB
11.14.1 UCB Company Information
11.14.2 UCB Overview
11.14.3 UCB Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.14.4 UCB Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 UCB Recent Developments
11.15 Desitin Arzneimittel
11.15.1 Desitin Arzneimittel Company Information
11.15.2 Desitin Arzneimittel Overview
11.15.3 Desitin Arzneimittel Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.15.4 Desitin Arzneimittel Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Desitin Arzneimittel Recent Developments
11.16 Amneal Pharmaceuticals
11.16.1 Amneal Pharmaceuticals Company Information
11.16.2 Amneal Pharmaceuticals Overview
11.16.3 Amneal Pharmaceuticals Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.16.4 Amneal Pharmaceuticals Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Amneal Pharmaceuticals Recent Developments
11.17 Organon Pharma
11.17.1 Organon Pharma Company Information
11.17.2 Organon Pharma Overview
11.17.3 Organon Pharma Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.17.4 Organon Pharma Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Organon Pharma Recent Developments
11.18 F.Hoffmann-La Roche
11.18.1 F.Hoffmann-La Roche Company Information
11.18.2 F.Hoffmann-La Roche Overview
11.18.3 F.Hoffmann-La Roche Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.18.4 F.Hoffmann-La Roche Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 F.Hoffmann-La Roche Recent Developments
11.19 Lundbeck
11.19.1 Lundbeck Company Information
11.19.2 Lundbeck Overview
11.19.3 Lundbeck Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.19.4 Lundbeck Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Lundbeck Recent Developments
11.20 Stada
11.20.1 Stada Company Information
11.20.2 Stada Overview
11.20.3 Stada Oral Medications for Parkinson's Disease Sales, Price, Revenue and Gross Margin (2019-2024)
11.20.4 Stada Oral Medications for Parkinson's Disease Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Stada Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Oral Medications for Parkinson's Disease Industry Chain Analysis
12.2 Oral Medications for Parkinson's Disease Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Oral Medications for Parkinson's Disease Production Mode & Process
12.4 Oral Medications for Parkinson's Disease Sales and Marketing
12.4.1 Oral Medications for Parkinson's Disease Sales Channels
12.4.2 Oral Medications for Parkinson's Disease Distributors
12.5 Oral Medications for Parkinson's Disease Customers
13 Oral Medications for Parkinson's Disease Market Dynamics
13.1 Oral Medications for Parkinson's Disease Industry Trends
13.2 Oral Medications for Parkinson's Disease Market Drivers
13.3 Oral Medications for Parkinson's Disease Market Challenges
13.4 Oral Medications for Parkinson's Disease Market Restraints
14 Key Findings in the Global Oral Medications for Parkinson's Disease Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer